Molecular downstaging: a new paradigm for neoadjuvant endocrine therapy
- PMID: 33490206
- PMCID: PMC7812196
- DOI: 10.21037/atm-20-5406
Molecular downstaging: a new paradigm for neoadjuvant endocrine therapy
Conflict of interest statement
Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure from (available at http://dx.doi.org/10.21037/atm-20-5406). The authors have no conflicts of interests to declare.
Comment on
-
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.Lancet Oncol. 2020 Jan;21(1):33-43. doi: 10.1016/S1470-2045(19)30786-7. Epub 2019 Dec 11. Lancet Oncol. 2020. PMID: 31838010 Clinical Trial.
References
-
- Ellis MJ, Suman VJ, Hoog J, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: Clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype - ACOSOG Z1031. J Clin Oncol 2011;29:2342-9. 10.1200/JCO.2010.31.6950 - DOI - PMC - PubMed
-
- Mustacchi G, Ceccherini R, Milani S, et al. Italian Cooperative Group GRETA Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol 2003;14:414-20. 10.1093/annonc/mdg117 - DOI - PubMed
-
- Gazet JC, Ford HT, Coombes RC, et al. Prospective randomized trial of tamoxifen vs surgery in elderly patients with breast cancer. Eur J Surg Oncol 1994;20:207-14. - PubMed
Publication types
LinkOut - more resources
Full Text Sources